Search Results - "Tanetsugu, Yusuke"

Development of a Sustainable Release System for a Ranibizumab Biosimilar Using Poly(lactic-co-glycolic acid) Biodegradable Polymer-Based Microparticles as a Platform by Tanetsugu, Yusuke, Tagami, Tatsuaki, Terukina, Takayuki, Ogawa, Takaya, Ohta, Masato, Ozeki, Tetsuya

“…Ranibizumab is a humanized monoclonal antibody fragment against vascular endothelial growth factor (VEGF)-A and is widely used to treat age-related macular…”
Get full text

Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia by Hino, Masayuki, Matsumura, Itaru, Fujisawa, Shin, Ishizawa, Kenichi, Ono, Takaaki, Sakaida, Emiko, Sekiguchi, Naohiro, Tanetsugu, Yusuke, Fukuhara, Kei, Ohkura, Masayuki, Koide, Yuichiro, Takahashi, Naoto

“…This open-label, single-arm, phase 2 study (ClinicalTrials.gov, NCT03128411) evaluated the efficacy, safety, and pharmacokinetics of bosutinib at a starting…”
Get full text

Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study by Ono, Takaaki, Hino, Masayuki, Matsumura, Itaru, Fujisawa, Shin, Ishizawa, Kenichi, Sakaida, Emiko, Sekiguchi, Naohiro, Ono, Chiho, Aizawa, Mana, Tanetsugu, Yusuke, Koide, Yuichiro, Takahashi, Naoto

“…Bosutinib has been evaluated for treatment of chronic-phase chronic myeloid leukemia (CP-CML) in several clinical studies, including in Japan. This open-label,…”
Get full text

Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis by Takahashi, Naoto, Cortes, Jorge E., Sakaida, Emiko, Ishizawa, Kenichi, Ono, Takaaki, Doki, Noriko, Matsumura, Itaru, García-Gutiérrez, Valentín, Rosti, Gianantonio, Ono, Chiho, Ohkura, Masayuki, Tanetsugu, Yusuke, Viqueira, Andrea, Brümmendorf, Tim H.

“…Bosutinib has been investigated in multiple clinical trials globally, including Japan, for treatment of chronic myeloid leukemia (CML). A pooled analysis of…”
Get full text

Development of a Sustainable Release System for a Ranibizumab Biosimilar Using Poly(lactic-co-glycolic acid) Biodegradable Polymer-Based Microparticles as a Platform by Yusuke Tanetsugua, Tatsuaki Tagamia, Takayuki Terukinaa, Takaya Ogawab, Masato Ohtab, Tetsuya Ozekia

“…Ranibizumab is a humanized monoclonal antibody fragment against vascular endothelial growth factor (VEGF)-A and is widely used to treat age-related macular…”
Get full text

Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study by Ono, Takaaki, Hino, Masayuki, Matsumura, Itaru, Fujisawa, Shin, Ishizawa, Kenichi, Sakaida, Emiko, Sekiguchi, Naohiro, Ono, Chiho, Aizawa, Mana, Tanetsugu, Yusuke, Koide, Yuichiro, Takahashi, Naoto

“…Introduction : Bosutinib is approved in Japan for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid…”
Get full text

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia by Takahashi, Naoto, Matsumura, Itaru, Fujisawa, Shin, Ishizawa, Kenichi, ONO, Takaaki, Sakaida, Emiko, Sekiguchi, Naohiro, Tanetsugu, Yusuke, Fukuhara, Kei, Ohkura, Masayuki, Koide, Yuichiro, Hino, Masayuki

“…Background: Bosutinib, a Src/Abl tyrosine kinase inhibitor, is approved at a starting dose of 500 mg once daily (QD) in many countries, including Japan, for…”
Get full text